
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:
Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:

The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

In 2024 alone, the global area planted with GM crops reached 218.7 million hectares, an increase of nearly 3.7 million hectares from 2023 and the highest level since the technology was first commercialised.

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
Also at STAT Biotech
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.

Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparticles, but variable feedstocks, scale-up hurdles, and thin safety data still stand between lab promise and reliable commercial bioprocessing.
A hybrid model provides hard-to-achieve insights into lactate performance during bioprocessing, creating conditions for more accurate predictions to better manage key batch parameters and variability.
A company developing extracellular vesicle-based products has developed a potency assay for quality control. They hope to adapt it for future products and scale it to commercial manufacturing.
Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials.
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.
The risk appears small and data is mixed, but FDA wants patients to be aware.
Also at CBS News, STAT Biotech
The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a…

Tam Anh General Hospital has completed an exclusive technology transfer from Japan's Grandsoul Medical Group covering immune cell and stem cell technologies being explored for treatment of cancer and chronic diseases.

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
WuXi AppTec’s shares jumped on Tuesday after the Pentagon removed the company from a list of entities allegedly linked to the Chinese military, marking a win for the biotech service giant and raising hopes among other mainland firms…

Illumina has announced an early access program to a duplex sequencing workflow that reads both DNA strands to detect trace ctDNA in molecular residual disease and tumor evolution studies. Kits are expected in early 2027.

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.

Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.

A study showed how E2F1 can trigger cell division without having to unpack the cell’s genetic material. Instead, it takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell.

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…

Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize.

Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up.